The MAPT gene, located on chromosome 17, encodes the tau protein, a key player in neurodegenerative disorders. Two common haplotypes—H1 and H2—are defined by a large inversion polymorphism that has been stable in human populations for millennia. According to ALZFORUM, the H1 haplotype has been consistently associated with increased risk for several neurodegenerative diseases, particularly Alzheimer’s disease, progressive supranuclear palsy, and corticobasal degeneration. This association has been replicated across multiple studies and populations, making H1 one of the strongest genetic risk factors identified for these conditions.

In contrast, the H2 haplotype appears to be protective or neutral in disease risk, though it is less common in global populations. The inversion distinguishing H1 and H2 suppresses recombination in this region, preserving distinct genetic lineages over time. This structural variation has implications not only for disease susceptibility but also for gene expression regulation, as the H1 haplotype is linked to higher MAPT expression in certain brain tissues.

For content creators in health, science, and wellness spaces, understanding the MAPT H1/H2 polymorphism offers a compelling narrative about how ancient genetic variations continue to influence modern health outcomes. It underscores the importance of genetics in neurodegenerative disease research and highlights potential avenues for future therapeutic targeting. As genetic screening and personalized medicine advance, haplotypes like H1/H2 may become more relevant in risk assessment and patient education—making this a timely topic for informed, evidence-based storytelling.